Vaxcyte’s 24-Valent Pneumococcal Vaccine Shows Best-In-Class Potential
Small Biotech Hopes To Compete In Big Pharma-Dominated Market
Executive Summary
The biotech’s share price jumps more than two-thirds as analysts hail top-line Phase I/II data as better than expected. Vaxcyte hopes to hold Phase III planning discussions with the FDA in 2023.
You may also be interested in...
Finance Watch: PTC Secures Up To $1bn In Funding From Blackstone
Public Company Edition: PTC will get $350m up front as part of an initial $500m commitment. Also, while Biohaven and Vaxcyte launched traditional follow-on offerings, Recursion and Agios took the private placement and royalty sale routes, while others revealed job cuts and other strategic updates.
Pfizer's Prevnar 20 Edges Closer To Infant Market, But Phase III Raises Some Questions
The pediatric market represents 70%-75% of the market for pneumococcal vaccines; Merck & Co.'s Vaxneuvance was already approved for infants earlier this year.
GSK Spies Pfizer Challenge With $2.1bn Vaccine Company Acquisition
GSK has spotted an opportunity to challenge Pfizer’s blockbuster Prevnar franchise, but the potential of Affinivax’s platform has yet to be proven.